CoChat

Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom

Open access

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The role of pulmonary hypertension as a cause of mortality in sickle cell disease (SCD) is controversial. METHODS AND RESULTS: We evaluated the relationship between an elevated estimated pulmonary artery systolic pressure and mortality in patients with SCD. We followed patients from the walk-PHaSST screening cohort for a median of 29 months. A tricuspid regurgitation velocity (TRV)≥ 3.0 m/s cuttof, which has a 67-75% positive predictive value for mean pulmonary artery pressure ≥ 25 mm Hg was used. Among 572 subjects, 11.2% had TRV ≥ 3.0 m/sec. Among 582 with a measured NT-proBNP, 24.1% had values ≥ 160 pg/mL. Of 22 deaths during follow-up, 50% had a TRV ≥ 3.0 m/sec. At 24 months the cumulative survival was 83% with TRV ≥ 3.0 m/sec and 98% with TRV < 3.0 m/sec (p < 0.0001). The hazard ratios for death were 11.1 (95% CI 4.1-30.1; p < 0.0001) for TRV ≥ 3.0 m/sec, 4.6 (1.8-11.3; p = 0.001) for NT-proBNP ≥ 160 pg/mL, and 14.9 (5.5-39.9; p < 0.0001) for both TRV ≥ 3.0 m/sec and NT-proBNP ≥ 160 pg/mL. Age > 47 years, male gender, chronic transfusions, WHO class III-IV, increased hemolytic markers, ferritin and creatinine were also associated with increased risk of death. CONCLUSIONS: A TRV ≥ 3.0 m/sec occurs in approximately 10% of individuals and has the highest risk for death of any measured variable. The study is registered in ClinicalTrials.gov with identifier: NCT00492531.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0099489

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study Flowchart.
Figure 1 Study Flowchart.CC0 · PubMed Central
Figure 2 Prevalence of TRV, BNP, Six Minute Walk Distance, and Fetal Hemoglobin. The screening study patient population consisted of 671 patients with sickle cell anemia, 632 of whom were followed for mortality over a median of 29 months. Ten percent (n = 64) had TRV measurements of 3.0 m/sec or higher and 80% (n = 508) had measurements less than 3.0 m/sec. TRV measurements were not available for 10% (n = 60) of the patient population (diagonal stripes). Twenty-two percent of patients (n = 140) had BNP measurements of 160 pg/mL or higher. Fourteen percent (n = 85) had six minute walk distances less than 332 meters, and 46% (n = 289) had fetal hemoglobin levels less than 5%.
Figure 2 Prevalence of TRV, BNP, Six Minute Walk Distance, and Fetal Hemoglobin. The screening study patient population consisted of 671 patients with sickle cell anemia, 632 of whom were followed for mortality over a median of 29 months. Ten percent (n = 64) had TRV measurements of 3.0 m/sec or higher and 80% (n = 508) had measurements less than 3.0 m/sec. TRV measurements were not available for 10% (n = 60) of the patient population (diagonal stripes). Twenty-two percent of patients (n = 140) had BNP measurements of 160 pg/mL or higher. Fourteen percent (n = 85) had six minute walk distances less than 332 meters, and 46% (n = 289) had fetal hemoglobin levels less than 5%.CC0 · PubMed Central
Figure 3 Kaplan-Meier Analysis of Survival Time by TRV and BNP. Longer survival times were observed for a) subjects with TRV less than 3.0 m/sec (p<0.0001) and b) for subjects with BNP levels less than 160 pg/mL (p = 0.0003).
Figure 3 Kaplan-Meier Analysis of Survival Time by TRV and BNP. Longer survival times were observed for a) subjects with TRV less than 3.0 m/sec (p<0.0001) and b) for subjects with BNP levels less than 160 pg/mL (p = 0.0003).CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 144

Metadata

Authors
Gladwin, M. T., Barst, R. J., Gibbs, J. S. R., Hildesheim, M., Sachdev, V., Nouraie, M., Hassell, K. L., Little, J. A., Schraufnagel, D. E., Krishnamurti, L., Novelli, E., Girgis, R. E., Morris, C. R., Berman Rosenzweig, E., Badesch, D. B., Lanzkron, S., Castro, O. L., Taylor, J. G., Goldsmith, J. C., Kato, G. J., Gordeuk, V. R., Machado, R. F., & on behalf of the walk-PHaSST Investigators and Patients
Affiliations
  • University of Pittsburgh (US)
  • Columbia University (US)
  • Imperial College London (GB)
  • National Heart, Lung, and Blood Institute (US)
  • Howard University (US)
  • University of Colorado Denver (US)
  • Case Western Reserve University (US)
  • University of Illinois Chicago (US)
  • Johns Hopkins University (US)
  • Emory University (US)
  • National Institutes of Health (US)
Corresponding author
Gladwin, Mark T.
Venue
PLoS ONE
Published
2014-07-02
Volume
9
Issue
7
Pages
e99489
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2121881033
Cited by
132
References
23
Citations by year
2026: 10 · 2025: 7 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 13 · 2020: 16 · 2019: 13 · 2018: 7 · 2017: 8 · 2016: 13 · 2015: 12 · 2014: 2
FWCI
5.85
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, public-domain)
  • Europe PMC (PubMed Central) (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Columbia Academic Commons (Columbia University)
Funders
  • U.S. Department of Health and Human Services
  • American Society of Hematology
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Gilead Sciences
  • Ikaria
  • United Therapeutics Corporation
  • Bayer Corporation
  • Hemophilia Center of Western Pennsylvania
  • International Union Against Tuberculosis and Lung Disease
  • National Institutes of Health
  • U.S. Public Health Service (HHSN268200617182C)
  • National Heart, Lung, and Blood Institute (P01HL103455, HHSN268200617182C, R01HL111656, K23HL083089)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
sickle cell disease, mortality risk factors, pulmonary hypertension, tricuspid regurgitation velocity, NT-proBNP, mean pulmonary artery pressure, survival, chronic transfusion, hemolysis, ferritin, creatinine
MeSH terms
Adult, Anemia, Sickle Cell, Blood Flow Velocity, Blood Pressure, Creatinine, Female, Ferritins, Follow-Up Studies, United Kingdom, Hemolysis, Humans, Hypertension, Pulmonary, Male, Middle Aged, Peptide Fragments, Risk Factors, Severity of Illness Index, United States, Cohort Studies, Proportional Hazards Models, Walking, Natriuretic Peptide, Brain, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. https://app.cochat.ai/papers/10.1371/journal.pone.0099489
The paper
Gladwin, M. T., Barst, R. J., Gibbs, J. S. R., Hildesheim, M., Sachdev, V., Nouraie, M., Hassell, K. L., Little, J. A., Schraufnagel, D. E., Krishnamurti, L., Novelli, E., Girgis, R. E., Morris, C. R., Berman Rosenzweig, E., Badesch, D. B., Lanzkron, S., Castro, O. L., Taylor, J. G., Goldsmith, J. C., . . . on behalf of the walk-PHaSST Investigators and Patients. (2014). Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLoS ONE. https://doi.org/10.1371/journal.pone.0099489

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.